The agency began its review into the class of weight loss and diabetes drugs, known as GLP-1 receptor agonists, last July after Iceland's health regulator flagged three cases of patients thinking about suicide or self-harm after using Novo's drugs - diabetes drug Ozempic and weight-loss treatment Saxenda.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/kHWSYve
via gqrds
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment